Taiho Oncology, Inc.
BiotechPrinceton, New Jersey, United States · Est. 2011
Taiho Oncology is a subsidiary of Otsuka Pharmaceutical Company focused on developing and commercializing innovative oncology medicines.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
68
Clinical Trials↗
All sponsored trials (all statuses)
3
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Phase 32
Phase 22
Phase 12
By Therapeutic Area
top 2
Oncology
457%
Hematology
114%
R&D Momentum
47/100
Pipeline Velocity
11/100
Trial Completion Rate
57/100
Pipeline Concentration
43/100
Pipeline Freshness
60/100
Strategic Signals
- ↗Active in Hematology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 10, 2026
Recruiting
A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)
Jul 10, 2026
Terminated
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma
Earlier
Jun 27, 2026TrialA Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
Jun 27, 2026TrialPhase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
Jun 27, 2026TrialAn Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
Oct 1, 2024TrialFutibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Dec 18, 2023TrialREZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Jul 13, 2023TrialPhase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
4 more events
May 25, 2023TrialA Study of TAS3351 in NSCLC Patients With EGFRmt
Dec 23, 2022TrialStudy to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Sep 30, 2022FDALytgobi — LYTGOBI
Dec 15, 2021TrialStudy to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
Oncologygastrointestinal cancerbreast cancer
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology
Oncology
Hematology
Oncology
Acute Myeloid Leukemia
CedazuridinePhase 2
ASTX660Phase 1
Advanced Cancer
ASTX660Phase 1
Myeloid Neoplasm
ASTX030Phase 3
CedazuridinePhase 3
Unknown / Other
Regulatory
Regulatory Timeline
20221 event
FDASep 30
Lytgobi — LYTGOBI
Application NDA214801 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)